Novel Oral Antiobesity Drug Shown to Reduce Body Weight by up to 13% in First-In-Human Study
EASD 2024: Amycretin was also found to be safe and well tolerated in adults with obesity and without diabetes.
21 Beliefs about AI in Health Care, from People Like Your Patients
AI is welcomed by US adults for streamlining the administrative complexity of getting medical care but not so much for replacing health care professionals themselves.
Recent Recreational Drug Use Ups Risk of Repeat Serious CV Event: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Updates Felinzanetant Label Warnings After Report of Severe Liver Injury
FDA heightened label warnings about hepatic injury and increased the required frequency of liver function testing after initiation of fezolinetant.
Good Cardiovascular Health Early on May Offset Genetic Risk of Hypertensive Disorders of Pregnancy
New data shows that favorable CV health in the first trimester is associated with a 35% to 62% lower risk of HDP regardless of level of genetic risk.
A False-Positive Breast Cancer Screening Result Discourages Future Mammography
Those least likely to schedule further screening mammograms had received a false-positive with recommendation for follow-up after only a short interval.
Corticosteroid Phobia among Individuals with Chronic Hand Eczema: Daily Dose
Mental Health Among Adolescents With Obesity: Daily Dose
Lilly Announces FDA Approval of Lebrikizumab-lbkz for Moderate to Severe Atopic Dermatitis
Among those treated with lebrikizumab, more than one-third saw clear/almost clear skin at week 16; three-quarters of them maintained results at week 52 with monthly dosing.
Investigational PACAP Inhibitor Reduces Monthly Migraine Days, Lundbeck Reports
Individuals with migraine who failed to respond to up to 4 previous migraine preventive treatments saw fewer monthly migraine and headache days after 1 infusion of Lu AG90222.
Axsome Therapeutics: FDA Accepts NDA Resubmission for AXS-07 for Acute Treatment of Migraine
Based on its acceptance of the resubmission, FDA has assigned a PDUFA action goal date of January 31, 2025 for AXS-07.
FDA Approves Dupilumab Label Expansion with Indication for CRSwNP in Adolescents
The approval makes dupilumab available to treat uncontrolled CRSwNP in adolescents aged 12 to 17 years, expanding on the current approved range of 18 years and older.
Awareness of Uncontrolled Hypertension Low, Particularly Among Young Adults, Study Warns
Unawareness was highest among the youngest adults, aged 18 to 44 years, an age range where CV health should be optimized to avoid later morbidity, researchers wrote.
Atrial Fibrillation in the US 3-Fold More Prevalent Than Previously Estimated, New Data Suggest
Approximately 10.5 million US adults, or 5% of the population, have the atrial fibrillation, according to new prevalence estimates.
How to Define an Atopic Dermatitis Flare: Survey Seeks New Patient Consensus
The term "flare" is used consistently in discussions of AD, but is everyone talking about the same thing? New research closes in on a patient-centered definition.
Best States for Health Care in the US: 2024
Which state retains the most medical residents? Or has the lowest cancer rate? Answers and more insights from a nationwide analysis, here.
GSK mRNA Flu Vaccine Candidate Delivers Favorable Topline Phase 2 Findings, Ready for Phase 3
The GSK reformulation induced acceptable immune responses for both influenza A and B strains, overcoming a setback earlier in the ability to successfully neutralize the latter.
Statin Plus Ezetimibe Outperforms High-Dose Statins in LDL-C Reduction: Daily Dose
sNDA Goes to FDA for neffy 1 mg for Young Children with Type 1 Allergic Reactions
The needle-free nasal spray, if approved, would be the first new administration method for epinephrine in young children in 35 years.
Mammography Centers Now Mandated to Disclose Breast Density
Regulations have been amended under the Mammography Quality Standards Act of 1992 to ensure women receive quality mammography for early breast cancer detection and prevention.
